Harnessing negative T-cell costimulatory pathways to promote engraftment

Transplant International

Volumn 21, Issue 1, 2008, Pages 18-20

  Popoola, Joyce ^a   Sayegh, Mohamed H ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; ENGRAFTMENT; GENETIC ENGINEERING; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; MACROPHAGE; MOLECULAR INTERACTION; NONHUMAN; NOTE; PHOSPHORYLATION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 36649018949     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00565.x     Document Type: Note

References (17)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970 160 : 1042.
2. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001 2 : 203.
3. Rothstein DM, Sayegh MH. T cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003 196 : 85.
4. Khoury SJ, Sayegh MH. The roles of new negative T cell co-stimulatory pathways in regulating autoimmunity. Immunity 2004 20 : 529.
5. Chen L, Hussein Y, Hwang KW, et al. Overexpression of program death-1 in T cells has mild impact on allograft survival. Transpl Int 2007 21 : 21.
6. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515.
7. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003 198 : 63.
8. Gao W, Demirci G, Strom TB, et al. Stimulating PD-1 negative signals concurrent with blocking CD154 co-stimulation induces long term islet allograft survival. Transplantation 2003 76 : 994.
9. Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005 174 : 3408.
10. Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003 198 : 71.
11. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand-1 in fetomaternal tolerance. J Exp Med 2005 202 : 231.
12. Iwai Y, Terawaki S, Ikegawa M, et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003 198 : 39.
13. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signasolome and downstream signaling to PKCtheta. FEBS Lett 2004 574 : 37.
14. Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell mediated alloimmune responses in vivo. J Immunol 2005 174 : 6648.
15. Koga N, Suzuki J, Kosuge H, et al. Blockade of the interaction between PD-1 and PDL-1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004 24 : 2057.
16. + regulatory T cell induced by ICOS-B7h blockade in-vivo. J Immunol 2007 179 : 786.
17. Tanaka K, Albin MJ, Yuan X, et al. PD-L1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007 in press.